Tag: VARIPULSE
J&J to showcase PFA advancements via multiple clinical and real-world studies...
Johnson & Johnson (J&J) MedTech has announced that new clinical and real-world data from its integrated-by-design Varipulse platform in pulsed field ablation (PFA) procedures for...
J&J unveils real-world results from VARIPURE substudy at ESC 2025
Johnson & Johnson (J&J) MedTech has today announced acute safety and effectiveness results from the VARIPURE substudy of the SECURE study evaluating the company’s Varipulse...
J&J launches Varipulse platform across Asia-Pacific region
Johnson & Johnson (J&J) MedTech has announced the launch of the Varipulse platform—a system used to perform catheter ablation procedures for the treatment of...
J&J MedTech presents new Omny-IRE and VARIPURE study data at HRS...
Johnson & Johnson (J&J) MedTech has announced positive initial three-month results from the Omny-IRE study evaluating the investigational Omnypulse platform in patients with paroxysmal...
J&J to resume Varipulse cases following ‘voluntary pause’ of US external...
Following a temporary, voluntary pause of US external evaluation and all US cases with its Varipulse catheter, Johnson & Johnson (J&J) is set to...
Cardiac Rhythm News’ top stories of 2024
From first-time clinical data to major industry debuts, here are Cardiac Rhythm News’ 10 most popular stories of 2024.
1. Abbott joins the pulsed field...
J&J MedTech receives US FDA approval for Varipulse PFA platform in...
Johnson & Johnson (J&J) MedTech has announced the US Food and Drug Administration (FDA) approval of the Varipulse pulsed field ablation (PFA) platform for...
HRS 2024: Late-breaking data explore safety and efficacy of Varipulse PFA...
Late-breaking results from the pivotal phase of the admIRE pivotal clinical trial, alongside results from the VIRTUE study—both assessing the Varipulse (Biosense Webster) pulsed...
Biosense Webster submits premarket approval application to US FDA for Varipulse...
Biosense Webster has submitted a premarket approval application (PMA) to the US Food & Drug Administration (FDA) for its Varipulse platform. The submission was...
Varipulse PFA system receives CE mark
Biosense Webster has announced the receipt of European CE mark approval for the Varipulse platform for the treatment of symptomatic drug refractory recurrent paroxysmal...
Biosense Webster supports VIRTUE and POLARIS studies of Varipulse PFA system
Biosense Webster has announced support for two collaborative studies, VIRTUE and POLARIS aiming to better understand the use and workflows with the investigational Varipulse...
AF Symposium hears late-breaking data on Varipulse PFA system
Twelve-month results from the inspIRE study, investigating predictors of success for pulmonary vein isolation with pulsed field ablation (PFA) using a variable loop catheter...
Varipulse PFA platform granted approval by Japanese Ministry of Health
Biosense Webster has today announced approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the Varipulse platform for the treatment of...
ADVERTORIAL: Pulsed field ablation: A new frontier in the treatment of...
This article was sponsored by Biosense Webster
According to data published by Patrick M McCarthy (Feinberg School of Medicine, Chicago, USA) and colleagues in the...